RadioimmunoguidedTM Surgery in Breast Cancer

  • Carol A. Nieroda
  • Edward MartinJr.
Chapter

Abstract

Twenty-two patients with biopsy proved carcinoma of the breast received radiolabeled MAb B723 (5–1 mCi of 125I per 2.0–0.25 mg MAb, Iodo-GenTM method) intravenously 6–30 days prior to definitive surgery (mastectomy or lumpectomy/axillary dissection). Using the Neoprobe 1000TM gamma detecting probe, gamma counts of breast and axillary tissues were obtained preoperatively, intraoperatively, and on ex vivo specimens. In breast tissue, the RIGSTM system identified tumor that was histopathologically confirmed in 11 of 14 patients. There were two false positives each having a histopathologic diagnosis of apocrine metaplasia and hyperplasia. Unsuspected tumor was histopathologically documented in 3 of 6 breast biopsies performed based on the preoperative presence of high external gamma counts in the countralateral breast or in a quadrant other than that of the original primary All six patients had negative mammograms and physical exams. The 3 false positives had diagnoses of aprocrine metaplasia and hyperplasia. In axillary tissue, probe counts identified metastatic disease in 3 of 8 patients and verified absence of disease in 10 of 14 patients. False positive counts were obtained in 4 having histopathologic diagnoses of sinus histocytosis or reactive nodes. RIGS appears to be able to identify residual, subclinical, and multicentric carcinoma of the breast and delineate the pattern of antigenic drainage of tumor into lymph nodes.

Keywords

Gamma Count Probe Count Gamma Detect Probe Apocrine Metaplasia Final Histopathological Diagnosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. 1.
    J. R. Harris, I. Henderson, D. W. Kinne, and S. Hellman. Cancer of the breast. in: Cancer:Principles and Practice of Oncology, V.T. DeVita, Jr., ed., S. Hellman, and S.A. Rosenblum. 3rd edition, pp. 1197–1268. Philadelphia: J. P.Lippincott Co., (1989).Google Scholar
  2. 2.
    A. Recht and J. R. Harris. Conservative surgery and radiation therapy for early breast cancer. In: Cancer:Principles and Practice of Oncology, Updates. V.T. DeVita, Jr., ed., S. Hellman and S.A. Rosenberg, 2nd ed., Vol. 2,pp.1–12. Philadelphia: J.B. Lippincott Co. (1987).Google Scholar
  3. 3.
    Treatment of Early Breast Cancer: NIH Consensus Development Conference. June 18–21, 1990, NIH, Bethesda, MD.Google Scholar
  4. 4.
    A. Thor, M. Weeks, and J. Schlom. Monoclonal antibodies and breast cancer. Seminars in Oncology 13:393 (1986).PubMedGoogle Scholar
  5. 5.
    J. Schlom, J. Greiner, P. Horan Hand, D. Colcher, G. Inghirami, M. Weeks, D. Pestka, P. Fisher, P. Nobuchi, and D. Kufe. Monoclonal antibodies to breast human cancer-associated antigens as potential reagents in the management of breast cancer. Cancer 54:2777 (1984).PubMedCrossRefGoogle Scholar
  6. 6.
    D. Colcher, P. Horan Hand, M. Nuti, and J. Schlom. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. 78:3199 (1981).PubMedCrossRefGoogle Scholar
  7. 7.
    E. E. Stems. Monoclonal antibodies in the diagnosis and treatment of carcinoma of the breast. Sing. Gynec. and Obs. 169:81 (1989).Google Scholar
  8. 8.
    R. L. Ceriani, M. Sasaki, H. Sussman, W. M. Wara, and E. W. Blank. Circulating mammary epithelial antigens in breast cancer. Proc. Natl. Acad. Sci. 79:5420 (1982).PubMedCrossRefGoogle Scholar
  9. 9.
    D. Colcher, M. Zalutsky, W. Kaplan, D. Kufe, F. Austin, and J. Schlom. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Research 43:736 (1983).PubMedGoogle Scholar
  10. 10.
    M. Nuti, Y. A. Teramoto, R. Mariani-Costantini, P. Horan Hand, D. Colcher, and J. Schlom. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int. J. Cancer 29:539 (1982).PubMedCrossRefGoogle Scholar
  11. 11.
    V. G. Johnson, J. Schlom, A. J. Paterson, J. Bennett, J. L. Magnani, and D. Colcher. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Research 46:850 (1986).PubMedGoogle Scholar
  12. 12.
    B. Sickle-Santanello, P. J. O’Dwyer, C. Mojzisik, S. E. Tuttle, G. H. Hinkle, M. Rousseau, J. Schlom, D. Colcher, M. O. Thurston, C. Nieroda, A. Sardi, J. P. Minton, and E.W. Martin. Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis. Colon Rectum 30:761 (1987).PubMedCrossRefGoogle Scholar
  13. 13.
    A. G. Siccardi, G. L. Buraggi, L. Callegaro, A. C. Colella, P. G. DeFilippi, G. Galli, G. Mariani, R. Masi, R. Palumbo, P. Riva, M. Salvatore, G. A. Scassellati, K. Scheidhauer, G. L. Turco, P. Zaniol, S. Benin, G. Deleide, M. Gasparini, S. Lastoria, L. Mansi, G. Paganelli, E. Salvischiani, E. Seregni, G. Viale, and P. G. Natali. Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab’)2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Research 49:3095 (1989).PubMedGoogle Scholar
  14. 14.
    A. A. Epenetos, S. Mather, M. Granowska, C. C. Nimmon, L. R. Hawkins, K. E. Britton, J. Shepherd, J. Taylor-Papadimitriou, H. Durbin, J. S. Malpas, and W. F. Bodmer. Targeting of iodine-123-labeled:tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet 2:999 (1982).PubMedCrossRefGoogle Scholar
  15. 15.
    A. M. Keenan, J. C. Harbert, and J. M. Larson. Monoclonal antibodies in nuclear medicine. J.Nucl. Med. 26:531 (1985).PubMedGoogle Scholar
  16. 16.
    M. S. Larson, Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J. Nucl. Med. 26:538 (1985).PubMedGoogle Scholar
  17. 17.
    D. M. Goldenberg, F. KeLand, E. Kin, S. Bennett, F. J. Primus, J. R. Van Nagell, N. Estes, P. DeSimone, and P. Rayburn. Use of radiolabelled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancer by external photoscanning, New Engl. J. Med. 298:1384 (1978).PubMedCrossRefGoogle Scholar
  18. 18.
    S. E. Order, J. L. Klein, D. Ettinger, P. Alderson, S. Siegelman, and P. Leichner. Use of isotopic inimui lobulin in therapy, Cancer Res. 40:3001 (1980).PubMedGoogle Scholar
  19. 19.
    J. P. Mach, F. Buchegger, M. Forni, J. Ritshard, D. Berche, J. D. Lumbroso, M. Screyer, C. Giradet, R. S. Accolla, and S. Carrel. Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinoma by external photoscanning and tomoscintigraphy, Immunol Today 2:239 (1986).CrossRefGoogle Scholar
  20. 20.
    B. Delaloye, A. Bischof-Delaloye, F. Buchegger, V. Von Fliedner, J. P. Grob, J. C. Volant, J. Pettavel, and J. P. Mach. Detection of colorectal carcinoma by emission-computerized tomography and after injection of 123I-labelled Fab or F(ab’)2fragments from monoclonal anticarcinoembryonic antigen antibodies, J.Clin.Invest. 77:301 (1986).PubMedCrossRefGoogle Scholar
  21. 21.
    R. M. Rainsbury. The localization of human breast carcinomas by radiolabelled monoclonal antibodies, Br. J.Surg. 71:805 (1984).PubMedCrossRefGoogle Scholar
  22. 22.
    D. M. Goldenberg, E.E. Kin, and F. H. KeLand. Human chorionic gonadotropic radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases, Proc. Natl. Acad. Sci. U.S.A. 78:7754 (1981).PubMedCrossRefGoogle Scholar
  23. 23.
    D. M. Goldenberg, E. E. Kin, F. J. DeLand, S. Bennett, and F. J. Primus. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res. 40:2984 (1980).PubMedGoogle Scholar
  24. 24.
    S. M. Larson, J. A. Carrasquillo, K. A. Krohn, B. W. Mc Griffin, D. Williams, I. Hellstrom, K. E. Hellstrom, and D. Lyster. Diagnostic imaging of malignant melooma with radiolabeled antitumor antibodies. JAMA 249:811 (1983).PubMedCrossRefGoogle Scholar
  25. 25.
    F. J. Primus and D. M. Goldenberg. Immunological considerations in the use of goat antibodies to carcinoembryonic antigen for the radioimmunodetection of cancer. Cancer Res.40:2979 (1980).PubMedGoogle Scholar
  26. 26.
    J. L. Murray, M. G. Rosenblum, and L. Laniki. Clinical parameters related to optimal tumor localization of Indium-111-labeled mouse anti melanoma monoclonal antibody ZEE-D18. J. Nucl. Med. 28: 25–33 (1987).PubMedGoogle Scholar
  27. 27.
    S. Lastoria and M. Salvatore. Diagnostic value of B72.3 monoclonal antibody in epithelial cancers. in: “Nuklearmedizin: New Trends and Possibilities in Nuclear Medicine”, H.A.E. Schmidt and L Cservay eds. Schattauer Verlag, p. 601 (1988).Google Scholar
  28. 28.
    O. A. Oredipe, R. F. Barth, S. E. Tuttle, D. M. Adams, I. Sautins, D. M. Gucci, C. M. Mojzisid, G. H. Hinkle, S. Jewell, Z. Steplewski, M. O. Thurston, and E. W. Martin Jr. Limits of sensitivity for the radioimmunodetection of colon cancer by means of a hand held gamma probe, Nucl. Med. Biol. 15: 595 (1988).Google Scholar
  29. 29.
    C. A. Nieroda, C. Mojzisik, G. Hinkle, M. O. Thurston, and E. W. Martin, Jr. Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer, Cancer Detection and Prevention, In press. (1990).Google Scholar
  30. 30.
    C. A. Nieroda, C. Mojzisik, A. Sardi, P. Ferrara, G. Hinkle, M. O. Thurston, and E. W. Martin, Jr., Radioimmunoguided surgery in primary colon cancer. Cancer Detection and Prevention 14: 651 (1990).PubMedGoogle Scholar
  31. 31.
    C. Nieroda, C. Mojzisik, A. Sardi, W. Farrar, G. Hinkle, M. Siddiqi, P. Ferrara, A. James, J. Schlom, M. Thurston, and E. W. Martin, Jr. Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3, Surg. Gynec. and Obst. 169:35–40 (1989).Google Scholar
  32. 32.
    C. A. Nieroda, C. Mojzisik, A. Sardi, P. Ferrara, G. Hinkle, M. O. Thurston, and E.W. Martin, Jr. The impact of radioimmunoguided surgery (RIGSTM) on surgical decision-making in colorectal cancer, Dis. Colon Rectum 32:927 (1989).PubMedCrossRefGoogle Scholar
  33. 33.
    A. Sardi, C. Agnone, C. Nieroda, C. Mojzisik, G. Hinkle, P. Ferrara, W. B. Farrar, J. Bolton, M. O. Thurston, and E. W. Martin Jr. Radioimmunoguided surgery in recurrent colorectal cancer: the role of carcinoembryonic antigen, computerized tomography, and physical examination, Southern Medical Journal, 82:1235 (1989).PubMedCrossRefGoogle Scholar
  34. 34.
    A. Sardi, M. Workman, C. Mojzisik, G. Hinkle, C. Nieroda, and E. W. Martin Jr. Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system), Arch Surg. 124:55 (1989).PubMedCrossRefGoogle Scholar
  35. 35.
    R. S. Kerbel. Implications of immunological heterogeneity of tumors, Nature. 280:358 (1979).PubMedCrossRefGoogle Scholar
  36. 36.
    L. E. Hart, and I. J. Fidler. The implications of tumor heterogeneity for studies on the biology and therapy of cancer metastases, Biochem. Biophys. Acta 651:37 (1981).PubMedGoogle Scholar
  37. 37.
    R. T. Prehn. Analysis of antigenic heterogeneity within individual 3-methylcholanthrene-induced mouse sarcomas, J. Natl. Cancer Inst. 45:1039 (1970).Google Scholar
  38. 38.
    M. V. Pimm, and R. W. Baldwin. Antigenic differences between primary methyl cholanthrene-induced rat sarcomas and post-surgical recurrences, Int. J. Cancer. 20:37 (1977).PubMedCrossRefGoogle Scholar
  39. 39.
    F. R. Miller, and G. H. Heppner. Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor, J. Natl. Cancer Inst. 63:1457 (1970).Google Scholar
  40. 40.
    G. Poste, J. Dolla, and I. J. Fidler. Interactions amoung clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B 16 melanoma cells, Proc. Natl. Acad.Sci. U.S.A.78:6226 (1981).PubMedCrossRefGoogle Scholar
  41. 41.
    J. Schlom, D. Colcher, P. Horan Hand, J. Greiner, D. Wunderlich, M. Weeks, P. B. Fisher, P. Noguchi, S. Pestka, and D. Kufe. Monoclonal antibodies reactive with breast tumor-associated antigens, Adv. Cancer Res.43:143 (1985).PubMedCrossRefGoogle Scholar
  42. 42.
    S. C. Lottich, W. W. Johnston, C. A. Szpak, E. R. Delong, A. Thor, and J. Schlom. Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions, Breast Cancer Res. Treatment. 6:49 (1985).Google Scholar
  43. 43.
    A. Thor, N. Ohuchi, C. A. Szpak, W. W. Johnson, and J. Schlom. Distribution of oncofetal antigen tumor-associated glycopotein-72 defined by monoclonal antibody B72.3, Cancer Res. 46:3118 (1986).PubMedGoogle Scholar
  44. 44.
    J. Lundy, M. Lozowski, and Y. Mishriki. Monoclonal antibody B72.3 as a diagnostic adjunct in fine needle aspirates of breast masses, Ann. Surg. 203:399 (1986).PubMedCrossRefGoogle Scholar
  45. 45.
    M. Castagna, M. Nuti, and F. Squartini. Mammary cancer antigen recognized by monoclonal antibody B72.3 in apocrine metaplasia of the human breast, Cancer Res. 47:902 (1987).PubMedGoogle Scholar
  46. 46.
    R. Muraro, M. Kuroki, D. Wunderlich, D. J. Poole, D. Colcher, A. Thor, J. W. Greiner, J. F. Simpson, A. Molinolo, P. Noguchi and J. Schlom. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen, Cancer Res. 48: 4588 (1988).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Carol A. Nieroda
    • 1
  • Edward MartinJr.
    • 2
  1. 1.Laboratory of Tumor Immunology and BiologyNational Cancer InstituteBethesdaUSA
  2. 2.Department of Surgery, College of MedicineOhio State UniversityColumbusUSA

Personalised recommendations